LegoChem Brings Late Christmas Cheer With $1.7bn ADC Deal

Janssen Gets Worldwide Rights To Trop2-Directed ADC

LegoChem Biosciences has sealed yet another sizable out-licensing agreement with a global big pharma firm, this time with Janssen, underlining the continued keen global interest in ADCs.

christmas gift
LegoChem/Janssen ADC Deal Biggest So Far For Korean Firm • Source: Shutterstock

More signs of improvement in South Korean biopharma alliances emerged right at the end of 2023, with LegoChem Biosciences, Inc. announcing an up to $1.7bn antibody-drug conjugate (ADC) deal with Janssen Biotech Inc. just after Christmas. 

More from South Korea

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By 

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.

Korea Needs To Think Bigger On M&As: KHIDI

 

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.

Japan-Korea Venture Collab Grows With VC And Regulatory Meetups

 
• By 

Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band

 
• By 

The latest activity in the South Korean biotech sector includes IPOs by Orum and Dongkook Life, as well as progress with ADCs at multiple firms.

More from Focus On Asia

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By 

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

Mounjaro In India: Price Differential, Window Of Opportunity

 

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By 

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.